loading...| Preferred Name |
metyrosine |
|
| Synonyms |
Alpha-methyl-p-tyrosine |
|
| Definitions |
A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C998" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C998" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000039501 |
|
| altLabel |
Alpha-methyl-p-tyrosine DEMSER Metirosine MK-781 methyl-tyrosine L-588357-0 |
|
| CAS Registry |
672-87-7 |
|
| Component of | ||
| cui |
C0051427 C0591337 C0886584 C1524091 C1524090 |
|
| definition |
A methylated tyrosine, a catecholamine synthesis antagonist with antihypertensive property. Metyrosine competitively inhibits tyrosine 3-monooxygenase, an enzyme that activates molecular oxygen to catalyze the hydroxylation of tyrosine to dihydroxyphenylalanine (Dopa), an intermediate to catecholamine (dopamine, norepinephrine, and epinephrine) production. This agent reduces the elevated levels of catecholamines associated with pheochromocytoma, thereby preventing hypertension. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C998" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C998" NCI Thesaurus) |
|
| Legacy PDQ ID |
2135 |
|
| LT |
TRD |
|
| NCI ID |
C998 |
|
| notation |
CDR0000039501 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
metyrosine |
|
| tui |
T116 T121 |